A study to see how combination of RMC-6291 and RMC-6236 is tolerated in multiple different dosages in participants with Advanced KRASG12C-mutated Solid Tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508178-27-00

Acronym

RMC-6291-101

Enrollment

110

Registered

2024-06-10

Start date

2024-07-10

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants with Advanced KRASG12C-Mutated Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Italy, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026